Summary

NICE (National Institute for Health and Clinical Excellence) reviews the cost effectiveness of medicines for the treatment of multiple sclerosis (annual cost per patient €10,000-18,000) and does not authorize their use within the UK National Health Service. However, an agreement between the manufacturers and the Department of Health is reached on an innovative risk sharing scheme.

Teaching objectives

Value pricing in the healthcare sector. Implications of value pricing for the main stakeholders (patients, physicians, payers, manufacturers). Implications of the adoption of cost effectiveness criteria by healthcare buyers for product development and international launch decisions of pharmaceutical companies.

Keywords
  • Pricing
  • Pharmaceuticals
  • Cost effectiveness
  • Technology assessment
  • HMI
  • Pharmaceutical and Medical Device Sectors